Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)
CNY 32.0
(7.02%)
CNY 32.0
(7.02%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -39.29 Million CNY | 40.56% |
| 2022 | -66.1 Million CNY | 67.8% |
| 2021 | -205.28 Million CNY | 67.59% |
| 2020 | -633.49 Million CNY | -639.22% |
| 2019 | -85.69 Million CNY | -14.33% |
| 2018 | -74.95 Million CNY | -1.66% |
| 2017 | -73.73 Million CNY | 23.29% |
| 2016 | -96.11 Million CNY | 0.0% |
| 2013 | -20.64 Million CNY | 61.16% |
| 2012 | -53.15 Million CNY | -138.88% |
| 2011 | -22.25 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -37.89 Million CNY | 20.89% |
| 2024 Q1 | -39.8 Million CNY | -1.29% |
| 2024 Q2 | -42.93 Million CNY | -7.86% |
| 2023 Q2 | -43.13 Million CNY | 6.09% |
| 2023 Q3 | -43.25 Million CNY | -0.28% |
| 2023 Q1 | -45.93 Million CNY | 30.52% |
| 2023 FY | -39.29 Million CNY | 40.56% |
| 2023 Q4 | -39.29 Million CNY | 9.15% |
| 2022 Q2 | -242.12 Million CNY | 19.16% |
| 2022 Q1 | -299.51 Million CNY | -45.9% |
| 2022 FY | -66.1 Million CNY | 67.8% |
| 2022 Q4 | -66.1 Million CNY | 16.88% |
| 2022 Q3 | -79.52 Million CNY | 67.15% |
| 2021 Q1 | -661.23 Million CNY | -4.38% |
| 2021 Q3 | -428.68 Million CNY | 15.57% |
| 2021 FY | -205.28 Million CNY | 67.59% |
| 2021 Q4 | -205.28 Million CNY | 52.11% |
| 2021 Q2 | -507.75 Million CNY | 23.21% |
| 2020 Q4 | -633.49 Million CNY | -16.2% |
| 2020 Q2 | -30.39 Million CNY | 52.19% |
| 2020 Q1 | -63.56 Million CNY | 25.82% |
| 2020 FY | -633.49 Million CNY | -639.22% |
| 2020 Q3 | -545.16 Million CNY | -1693.75% |
| 2019 Q2 | -75.98 Million CNY | 0.0% |
| 2019 FY | -85.69 Million CNY | -14.33% |
| 2019 Q4 | -85.69 Million CNY | 0.0% |
| 2018 FY | -74.95 Million CNY | -1.66% |
| 2017 FY | -73.73 Million CNY | 23.29% |
| 2016 FY | -96.11 Million CNY | 0.0% |
| 2014 Q3 | -18.7 Million CNY | 0.0% |
| 2013 FY | -20.64 Million CNY | 61.16% |
| 2012 FY | -53.15 Million CNY | -138.88% |
| 2011 FY | -22.25 Million CNY | 0.0% |